ERBB2 and breast carcinoma: In patients with human epidermal growth factor receptor 2 positive (HER2 +) metastatic breast cancer, drug therapy with the monoclonal antibody (mAb), trastuzumab, is effective in controlling extra-central nervous system (CNS) metastases but not in controlling the intra-CNS disease5.